Results 111 to 120 of about 21,874 (160)

Soluble isoforms of EGFR family in breast cancer: Advances and clinical relevance (Review). [PDF]

Oncol Lett
Yang P, Jiang X, He F.
europepmc   +1 more source

Quantitative Modeling of Lipid Droplet Contribution to Intracellular Drug Distribution and Efficacy of Tyrosine Kinase Inhibitors. [PDF]

ACS Omega
Liu X, Woo S.
europepmc   +1 more source

Hydrazonylthiazole Derivatives as Dual EGFR and ALR2 Inhibitors: Design, Synthesis, and Comprehensive In Vitro and In Silico Evaluation for Potential Anticancer Activity. [PDF]

Pharmaceuticals (Basel)
Sever B, Türkeş C, Demir Y, Elamin KM, Osman W, Oral K, Akıncı Genç S, Cantürk Z, Masunaga T, Kishimoto N, Misumi S, Otsuka M, Fujita M, Ciftci H.   +13 more
europepmc   +1 more source

IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumors. [PDF]

Sci Adv
Banu K, Khan MA, Li S, Reynolds-Gagliano M, Wang X, Mobley RJ, Barnett KR, Wielgosz MM, Bauler M, Wincek C, Kodali K, Wang W, Pagala V, High AA, Putnam D, Kotecha RS, Cheung LC, Ma X, Throm RE, Pruett-Miller SM, Savic D, Brady SW.   +21 more
europepmc   +1 more source

Potential repurposing of lapatinib and pazopanib as neuroprotective agents in a rat model of Huntington's disease. [PDF]

Inflammopharmacology
Ezeldine-Elmahalawy N, Abdelkader NF, Zaki HF, Elbrairy AI, Gad SS.   +4 more
europepmc   +1 more source

Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Literature Overview. [PDF]

Cancers (Basel)
Gorzelak-Magiera A, Kabut J, Sadurska J, Długaszek A, Domagała-Haduch M, Szot A, Gisterek-Grocholska I.   +6 more
europepmc   +1 more source

The Role of Lipid Metabolism in the Progression of Breast Cancer. [PDF]

J Cancer
Liu TT, Wang MM.
europepmc   +1 more source

The inhibitory effect of tyrosine kinase inhibitors on angiogenesis in zebrafish and interrelationship with the activation of the PI3K/AKT pathway. [PDF]

BMC Pharmacol Toxicol
Yang L, Liu X.
europepmc   +1 more source

Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer. [PDF]

Technol Cancer Res Treat
Shang A, Xiong Y, Li M, Tang W, Wan K, Deng Z, Mao X, Chen H.   +7 more
europepmc   +1 more source

Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancer. [PDF]

Breast Cancer Res
Yoshida T, Wei F, Kouro T, Kawaguchi K, Kataoka TR, Yasojima H, Bando H, Kuwayama T, Nakamura R, Nagai SE, Masuda N, Toi M, Sasada T.   +12 more
europepmc   +1 more source